Cargando…

Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?

A high Mandard score may indicate the tumor is insensitive to chemotherapy. We analyzed tumor regression and lymph node response under different Mandard scores to assess the impact of Mandard score on prognosis. Methods. Mandard scores and ypN stage of postoperative pathological reports were recorde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Wen-Zhe, Wang, Bing-Zhi, Li, Deng-Feng, Jiang, Zhi-Chao, Xiong, Jian-Ping, Li, Yang, Jin, Peng, Shao, Xin-Xin, Hu, Hai-Tao, Tian, Yan-Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975703/ https://www.ncbi.nlm.nih.gov/pubmed/35369117 http://dx.doi.org/10.1155/2022/8178184

Ejemplares similares

Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma
por: Tong, Yilin, et al.
Publicado: (2021)

A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy
por: Xu, Quan, et al.
Publicado: (2022)

Prognostic Value of Mandard’s Tumor Regression Grade (TRG) in Post Chemo-Radiotherapy Cervical Cancer
por: Scaglione, Giulia, et al.
Publicado: (2023)

Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study
por: Li, Yang, et al.
Publicado: (2020)

Laparoscopic vs open total gastrectomy for advanced gastric cancer following neoadjuvant therapy: A propensity score matching analysis
por: Hu, Hai-Tao, et al.
Publicado: (2022)

Prognostic Value of Mandard and Dworak Tumor Regression Grading in Rectal Cancer: Study of a Single Tertiary Center
por: Santos, Marisa D., et al.
Publicado: (2014)

Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2021)

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer
por: Sun, Kai-Yu, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
por: Tong, Xie, et al.
Publicado: (2023)

Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma
por: Zhang, Guo-Yi, et al.
Publicado: (2015)

Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis
por: Kano, Masayuki, et al.
Publicado: (2019)

Change of SPARC expression after chemotherapy in gastric cancer
por: Gao, Yong-Yin, et al.
Publicado: (2015)

Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes
por: Liu, Yi, et al.
Publicado: (2018)

Propensity-score-matching-based analysis of laparoscopic gastrectomy with neoadjuvant chemotherapy for gastric carcinoma
por: Furuta, Shimpei, et al.
Publicado: (2021)

Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer
por: Jiang, Lin, et al.
Publicado: (2021)

Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer
por: Liu, Jianyu, et al.
Publicado: (2022)

Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy
por: Feng, Daofu, et al.
Publicado: (2015)

Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy
por: Deng, Zhi-Ping, et al.
Publicado: (2017)

Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study
por: Wang, Xin, et al.
Publicado: (2022)

A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High‐Grade Bone Sarcomas: A Multicenter Study
por: He, Fangzhou, et al.
Publicado: (2022)

Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma
por: Borg, David, et al.
Publicado: (2018)

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

Benefit of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Bidirectional Chemotherapy for Patients with Gastric Cancer with Peritoneal Carcinomatosis Considering Cytoreductive Surgery
por: Yu, Hsin-Hsien, et al.
Publicado: (2023)

Indications of neoadjuvant chemotherapy for locally advanced Gastric Cancer patients based on pre-treatment clinicalpathological and laboratory parameters
por: Wang, Yue, et al.
Publicado: (2020)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Modified stomach-partitioning gastrojejunostomy for initially unresectable advanced gastric cancer with outlet obstruction: A case report
por: Shao, Xin-Xin, et al.
Publicado: (2023)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
por: Li, Ziyu, et al.
Publicado: (2020)

Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2020)

Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis
por: Yuan, Shu-Qiang, et al.
Publicado: (2017)

Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy
por: Ma, Wen-juan, et al.
Publicado: (2022)

Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis
por: Zhai, Yuhao, et al.
Publicado: (2023)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching
por: Zhang, Chenggang, et al.
Publicado: (2023)

Perioperative versus total neoadjuvant chemotherapy in gastric cancer
por: Yang, Jessica, et al.
Publicado: (2023)

Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy
por: Wu, Zhen-Feng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hktmoi7u3chqkntmh1ns8qslub